A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

This study is comparing a new antibody-drug conjugate called SHR-A2009 combined with aumolertinib (an EGFR-targeted drug) versus aumolertinib alone in people with advanced non-small cell lung cancer whose tumors have EGFR mutations and have not received any prior systemic treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced, metastatic, or recurrent non-small cell lung cancer with confirmed EGFR mutations (in tissue or blood) - You have not previously received systemic treatment for this stage of lung cancer - You have at least one measurable tumor on imaging - Your general health is good (ECOG 0-1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your cancer is confirmed to be small cell lung cancer mixed with NSCLC - You have active brain metastases that are unstable or untreated - You have serious organ function problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.